Sunitinib Malate Activates Fas/FasL and Caspase-3/8 Pathway in Keratinocytes
碩士 === 國立陽明大學 === 藥理學研究所 === 100 === BACKGROUND：Sunitinib malate is an orally administered inhibitor of tyrosine kinases, which has been approved for the treatment of metastatic renal cell carcinoma (mRCC) and imatinib-resistant gastrointestinal stromal tumor (GIST). However, the cutaneous adverse r...
| Main Authors: | , |
|---|---|
| Other Authors: | |
| Format: | Others |
| Language: | zh-TW |
| Published: |
2012
|
| Online Access: | http://ndltd.ncl.edu.tw/handle/59315608670845306909 |